BOLD — Boundless Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1782303 ·
Last close
$1.47
Market Cap
$33.02M
52W High
$1.68
52W Low
$1.07
ADV30
359,409
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -14,475,000 | -13,555,000 | 140,970,000 | 17,483,000 | 54,587,000 |
| Dec 2025 | 0 | — | -14,002,000 | -12,885,000 | 157,059,000 | 17,868,000 | 58,405,000 |
| Sep 2025 | 0 | — | -15,148,000 | -13,879,000 | 168,721,000 | 14,980,000 | 58,552,000 |
| Jun 2025 | 0 | — | -17,061,000 | -15,675,000 | 179,453,000 | 14,697,000 | 56,762,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-46,661,000
Investing CF
$37,801,000
Financing CF
$141,000
CapEx
$-546,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.61
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-259,669,000
Inventory
—
Receivables
—
ST Investments
$89,713,000
EBIT TTM
$-63,552,000
Pretax Income TTM
$-58,197,000
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -63,552,000 | -58,197,000 | 157,059,000 | 58,405,000 | — | -46,661,000 |
| Dec 2024 | 0 | -73,267,000 | -65,363,000 | 206,409,000 | 55,767,000 | — | -60,841,000 |
| Dec 2023 | 0 | -54,796,000 | -49,434,000 | 129,894,000 | 256,976,000 | — | -46,855,000 |
| Dec 2022 | 0 | -46,469,000 | -45,901,000 | 76,829,000 | 158,525,000 | — | -39,596,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.28
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NSRX | Nasus Pharma Ltd | $33.14M | $2.83 | — |
| ABVC | ABVC BIOPHARMA, INC. | $33.54M | $1.29 | — |
| TVRD | Tvardi Therapeutics, Inc. | $32.27M | $3.44 | — |
| NNVC | NANOVIRICIDES, INC. | $34.40M | $1.51 | — |
| NRSN | NeuroSense Therapeutics Ltd. | $31.48M | $0.87 | — |
News headlines (Yahoo Finance, 1h cache)
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-08 11:00 · Yahoo
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
2026-04-17 20:49 · Yahoo
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
2026-03-17 20:52 · Yahoo
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
2026-03-09 11:00 · Yahoo
Boundless Bio to Participate in the Leerink Global Healthcare Conference
2026-03-04 12:00 · Yahoo
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why
2026-02-13 17:00 · Yahoo
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
2026-02-05 12:00 · Yahoo
We're Keeping An Eye On Boundless Bio's (NASDAQ:BOLD) Cash Burn Rate
2026-01-31 14:19 · Yahoo
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
2026-01-20 12:00 · Yahoo
Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference
2025-11-24 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.